Qiagen Plans to Buy Cancer MDx Firm Ipsogen for $101M

Qiagen has entered into exclusive negotiations to acquire 47 percent of Ipsogen's stock. After the completion of that deal, Qiagen would move to acquire all remaining shares of the French cancer molecular diagnostic firm.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories